Tralokinumab rapidly improves subjective symptoms and quality of life in patients with moderate-to-severe atopic dermatitis: a real-life 16-week experience

Click to increase image sizeClick to decrease image size

Ethical approval

Institutional review board approval was exempted, as the study procedures did not deviate from standard clinical practice. All included patients had provided written informed consent for the retrospective analysis of their clinical data. The study was conducted in accordance with the Helsinki Declaration of 1964 and its later amendments.

Disclosure statement

L. Gargiulo has been a consultant for Almirall. M. Valenti has been a consultant and/or speaker for Sanofi, Leo Pharma, Eli Lilly, Novartis, Janssen, AbbVie, and Boehringer Ingelheim. A. Costanzo has served as an advisory board member, consultant and has received fees and speaker’s honoraria or has participated in clinical trials for Abbvie, Almirall, Biogen, LEO Pharma, Lilly, Janssen, Novartis, Pfizer, Sanofi Genzyme, and UCB-Pharma. A. Narcisi has served on advisory boards, received honoraria for lectures and research grants from Almirall, Abbvie, Leo Pharma, Celgene, Eli Lilly, Janssen, Novartis, Sanofi‐Genzyme, Amgen, and Boehringer Ingelheim. L. Ibba, P. Facheris, and C. A. Vignoli have nothing to declare.

Data availability statement

Additional data supporting the findings of this manuscript are available on reasonable request to the corresponding author.

Additional information

Funding

None.